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Summary
Background Wilms tumour is the most common childhood renal cancer and is genetically heterogeneous. While 
several Wilms tumour predisposition genes have been identified, there is strong evidence that further predisposition 
genes are likely to exist. Our study aim was to identify new predisposition genes for Wilms tumour.
Methods In this exome sequencing study, we analysed lymphocyte DNA from 890 individuals with Wilms tumour, 
including 91 affected individuals from 49 familial Wilms tumour pedigrees. We used the protein-truncating variant 
prioritisation method to prioritise potential disease-associated genes for further assessment. We evaluated new 
predisposition genes in exome sequencing data that we generated in 334 individuals with 27 other childhood cancers 
and in exome data from The Cancer Genome Atlas obtained from 7632 individuals with 28 adult cancers.
Findings We identified constitutional cancer-predisposing mutations in 33 individuals with childhood cancer. The 
three identified genes with the strongest signal in the protein-truncating variant prioritisation analyses were TRIM28, 
FBXW7, and NYNRIN. 21 of 33 individuals had a mutation in TRIM28; there was a strong parent-of-origin effect, 
with all ten inherited mutations being maternally transmitted (p=0·00098). We also found a strong association with 
the rare epithelial subtype of Wilms tumour, with 14 of 16 tumours being epithelial or epithelial predominant. There 
were no TRIM28 mutations in individuals with other childhood or adult cancers. We identified truncating FBXW7 
mutations in four individuals with Wilms tumour and a de-novo non-synonymous FBXW7 mutation in a child with a 
rhabdoid tumour. Biallelic truncating mutations in NYNRIN were identified in three individuals with Wilms tumour, 
which is highly unlikely to have occurred by chance (p<0·0001). Finally, we identified two de-novo KDM3B mutations, 
supporting the role of KDM3B as a childhood cancer predisposition gene.
Interpretation The four new Wilms tumour predisposition genes identified—TRIM28, FBXW7, NYNRIN, and 
KDM3B—are involved in diverse biological processes and, together with the other 17 known Wilms tumour 
predisposition genes, account for about 10% of Wilms tumour cases. The overlap between these 21 constitutionally 
mutated predisposition genes and 20 genes somatically mutated in Wilms tumour is limited, consisting of only four 
genes. We recommend that all individuals with Wilms tumour should be offered genetic testing and particularly, 
those with epithelial Wilms tumour should be offered TRIM28 genetic testing. Only a third of the familial Wilms 
tumour clusters we analysed were attributable to known genes, indicating that further Wilms tumour predisposition 
factors await discovery.
Funding Wellcome Trust.
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
Wilms tumour is a childhood kidney tumour that affects 
one in 10 000 children. Its histology is similar to that of 
the developing kidney and is typically triphasic, with 
blastemal, stromal, and epithelial components.1 Biphasic 
tumours, with two of the three components, and mono­
morphic tumours consisting of only one component also 
occur but are rarer.1
Wilms tumour is primarily a non­familial condition, 
with only about 2% of affected individuals having a relative 
with the tumour.2 Given its rarity, inherited causes—rather 
than chance—are assumed to underlie familial clusters, 
and several have been reported, including constitutional 
mutations in the genes WT1, CTR9, and REST.2–4 Wilms 
tumour is also known to be associated with many genetic 
conditions, including the WAGR, Denys­Drash, Beckwith­
Wiedemann, Simpson­Golabi­Behmel, Perlman, mosaic 
variegated aneuploidy, hereditary hyperparathyroidism­
jaw tumour, Li­Fraumeni, DICER1, and Bohring­Opitz 
syndromes, Fanconi anaemia, and PIK3CA­related over­
growth spectrum.2–11 These conditions are diverse in their 
clinical and histological associations, inheritance patterns, 
and mutational mechanisms of pathogenicity. The under­
lying predisposition genes have many different functions 
and are involved in diverse biological processes. The 
identification of these genes and investigations into their 
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role in Wilms tumour predisposition have led to 
fundamental insights into developmental, cellular, and 
oncological mechanisms and have important clinical 
implications for individuals with Wilms tumour and their 
families.2–11 Furthermore, many causes of familial and 
syndromic Wilms tumour also contribute to non­familial, 
non­syndromic Wilms tumour.2,4,5
Research over the past 25 years has led to tremendous 
advances in our knowledge of Wilms tumour pre­
disposition. However, available evidence suggests that 
our knowledge is still incomplete and that further 
predisposition factors remain to be discovered. In 
particular, the cause of many familial clusters is still 
unknown.4 In this study, we aimed to use exome 
sequencing to identify new Wilms tumour predisposition 
genes and to characterise and contextualise the genetic 
landscape of such predisposition.
Methods
Study design and participants
In this exome sequencing study, we included participants 
recruited to the Factors Associated with Childhood 
Tumours (FACT) Study. All children with a childhood 
solid tumour from the UK were eligible for participation 
in the FACT study; children with familial childhood 
cancer anywhere in the world were also eligible for 
participation in the FACT study. We analysed lymphocyte 
DNA from 1215 individuals with 28 different childhood 
tumours, of whom 1206 had one childhood tumour and 
nine individuals had two different childhood tumours 
(appendix). This cohort included 890 individuals with 
Wilms tumour: 799 had non­familial disease and 
91 were from 49 familial Wilms tumour pedigrees in 
which two or more individuals had Wilms tumour due 
to an unknown genetic or epigenetic cause (figure 1; 
appendix). Most participants with Wilms tumour were 
from the UK and, therefore, were likely to have been 
treated with chemotherapy before surgery. We used con­
stitutional (germline) exome data from 7632 individuals 
with 28 different adult cancers available from The 
Cancer Genome Atlas (TCGA) on May 13, 2014  (figure 1; 
see appendix for the types and number of adult cancers 
interrogated). As reference data, we used the Exome 
Aggregation Consortium (ExAC) data, version 3, 
accessed on Nov 13, 2015 (excluding the TCGA 
samples),12 and the ICR1000 UK exome series.13 We 
generated and analysed the ICR1000 UK exome series 
and childhood cancer sample data from the FACT 
participants by use of consistent sequencing and 
analytical processes.
The FACT study was approved by the London 
Multicentre Ethics Committee (05/MRE02/17), and its 
collaborators are listed in the appendix. Written informed 
consent was obtained from all participants, their parents 
or guardians, or both, as appropriate (age cutoff for 
consent was 18 years).
Procedures
We did exome sequencing in samples from all childhood 
cancer probands and 119 individuals from 49 familial 
See Online for appendix
For The Cancer Genome Atlas see 
https://cancergenome.nih.gov
Research in context
Evidence before this study
Wilms tumour is a rare childhood kidney tumour. We searched 
PubMed for papers in English with the terms “Wilms” AND 
“genetic” OR “mutation” OR “familial” OR “syndrome”, yielding 
2801 papers that we reviewed to identify those relevant to 
genetic predisposition to Wilms tumour. This review identified 
17 genes previously shown to predispose to Wilms tumour and 
showed that further Wilms tumour predisposition genes must 
exist, because many syndromic cases and familial clusters have 
not been explained.
Added value of this study
To our knowledge, this study is the largest exome sequencing 
study to date of individuals with Wilms tumour, involving 
890 individuals, including 91 individuals from 49 familial 
Wilms tumour pedigrees. We identified four new Wilms 
tumour predisposition genes, TRIM28, FBXW7, KDM3B, and 
NYNRIN. We showed that FBXW7 and KDM3B are pleiotropic 
cancer predisposition genes, and that KDM3B and NYNRIN 
might also cause non-malignant phenotypes, particularly 
intellectual disability. Our study identified TRIM28 as a major 
Wilms tumour predisposition gene, making a similar 
contribution to familial and unselected Wilms tumour as 
those of constitutional WT1 and REST mutations. We also 
found an association between TRIM28 mutations and 
epithelial histology and a strong parent-of-origin-effect, 
because all inherited TRIM28 mutations were maternally 
transmitted. Functional enrichment analyses revealed 
remarkable diversity in the biological pathways affected by 
Wilms tumour predisposition genes. We also found limited 
overlap between the 21 constitutionally mutated Wilms 
tumour predisposition genes and 20 genes somatically 
mutated in Wilms tumour.
Implications of all the available evidence
This study provides new insights into the causes of Wilms 
tumour and describes the overall landscape of Wilms tumour 
predisposition. Wilms tumour shows remarkable genetic 
heterogeneity and aetiological complexity, which have 
substantial clinical impact. Genetic testing should be made 
available to individuals with Wilms tumour, but will need to 
encompass both broad genetic testing, for example by exome 
sequencing, and testing for 11p15 epigenetic abnormalities. 
Moreover, our findings suggest that more Wilms tumour 
predisposition genes are likely to exist, which will have 
relevance for future research and clinical testing.
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Wilms tumour pedigrees who did not have Wilms 
tumour, by using 50 ng genomic DNA and the Nextera 
DNA sample preparation kit (Illumina, San Diego, CA, 
USA) or 1·5 µg genomic DNA and the TruSeq exome 
enrichment kit (Illumina). The captured libraries were 
amplified by PCR with the supplied paired­end PCR 
primers. Sequencing was done with HiSeq 2000 
(Illumina) or HiSeq 2500 (Illumina). We used the 
OpEx v1.0 pipeline to do variant calling in childhood 
cancer, adult cancer (TGCA), and ICR1000 exome data.14 
We also reannotated the variants in the ExAC data with 
the CAVA tool in OpEx, to ensure variant calling 
consistency across the different cohorts.14 We used 
the protein­truncating variant prioritisation method to 
prioritise potential disease­associated genes for follow­
up; this is a proven strategy for identifying tumour 
suppressor genes in outbred populations, which we have 
used to identify several other cancer predisposition 
genes.3,4,10 We validated variants in TRIM28, FBXW7, 
NYNRIN, and KDM3B genes by use of Sanger 
sequencing in the probands and any available relatives, 
designing primers with BatchPrimer3. We used the 
QIAGEN Multiplex PCR kit (QIAGEN, Hilden, Germany) 
to prepare PCRs, and the resulting amplicons were 
bidirectionally sequenced with BigDye Terminator cycle 
sequencing kits (Thermo Fisher Scientific, Waltham, 
MA, USA) and an ABI 3730 sequencer (Life Technologies, 
Carlsbad, CA, USA). We analysed sequencing traces with 
Mutation Surveyor software and by visual inspection 
with Chromas, version 2.13. We validated the CDC73 
mutation with the TruSight Cancer panel (Illumina). We 
did in­silico analyses of variant pathogenicity with 
Alamut Visual, version 2.9.0.
Statistical analysis
We used the methods described by Akawi and 
colleagues15 to obtain the probability of a family in our 
study having two protein­truncating variants in a given 
gene. The method uses the frequency of rare protein­
truncating variants (allele frequency <0·001) in ExAC 
and the number of observed protein­truncating variants 
in a given gene to estimate the probability of an 
individual having two of these variants in that gene. The 
baseline prevalence of having two protein­truncating 
variants per gene is calculated as the proportion of rare 
protein­truncating variants squared. We observed two 
individuals with two protein­truncating variants and 
nine individuals with a single protein­truncating variant 
in NYNRIN among 844 individuals with Wilms tumour 
from the 890 included in this study. We used the 
R function to calculate the probability of observing 
two individuals with two NYNRIN protein­truncating 
variants: analyse_inherited_enrichment from the 
R package recessiveStats with hgnc=”NYNRIN”, 
chrom=“14”, counts$biallelic_lof=2, counts$lof_func=9, 
and cohort_n=844.
We used a binomial test—dbinom function in R—to 
calculate the probability of all ten TRIM28 mutations 
with known inheritance being maternally inherited, 
assuming the baseline probability of inheriting the 
variant from either parent was 0·5.
We did a functional enrichment analysis with use of 
g:Profiler (version r1665_e85_eg32).16 We used the 
21 predisposition genes described for Wilms tumour as 
our query set. We looked for enrichment among Gene 
Ontology molecular function terms and pathway gene 
sets from the Kyoto Encyclopedia of Genes and Genomes, 
requiring the size of the functional category to have a 
minimum of five genes and using the Benjamini­
Hochberg correction for multiple testing p value as the 
significance threshold. The false discovery rate q values 
presented in this study are the Benjamini­Hochberg 
critical values.
For the somatic cancer driver comparisons, we used 
20 genes reported to be somatically mutated in Wilms 
tumour. These included 17 established genes reported in 
more than one publication and three newly reported 
genes (ACTB, BCOR, NONO) with at least three somatic 
mutations in the TARGET discovery series.17 We used 
the COSMIC cancer gene census to establish which of 
the 21 Wilms tumour predisposition genes, and which of 
the 20 somatically mutated Wilms tumour driver genes, 
were also somatically mutated in other cancer types.
Role of the funding source
The funder of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. SM, SY, EH, and NR had full 
access to all the data. The corresponding author had 
full access to all the data in the study and had final 
responsibility for the decision to submit for publication. 
For the COSMIC cancer gene 
census see https://cancer.sanger.
ac.uk/census
Figure 1: Cancer cohorts investigated
Wilms tumour families are pedigrees in which two or more individuals had Wilms 
tumour. FACT=Factors Associated with Childhood Tumours. TCGA=The Cancer 
Genome Atlas. *Nine individuals had two different childhood tumours.
1215 individuals with
           28 different childhood
 tumours (FACT study)
7632 individuals with
           28 different adult 
 tumours (TCGA)
890 individuals with
 Wilms tumour
334* individuals with
           27 different
           childhood
           tumours
8847 individuals with cancer
799 individuals with
 non-familial
 Wilms tumour
91 individuals with
 familial Wilms
 tumour from
     49 families
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Results
We used the protein­truncating variant prioritisation 
method with dominant and recessive inheritance 
models to identify genes with different protein­
truncating variants in 890 individuals with Wilms 
tumour (figure 1). The three genes with the strongest 
signal in the prioritisation analyses were TRIM28, 
FBXW7, and NYNRIN. We did Sanger sequencing to 
validate protein­truncating variants and rare non­
synonymous variants of these genes in probands 
and any available samples from relatives to further 
evaluate their status as bona fide Wilms tumour pre­
disposition genes.
We identified pathogenic truncating mutations of 
TRIM28 in 17 individuals with Wilms tumour from 
13 families (figure 2, table, appendix). At least three of 
these truncating mutations had arisen de novo. Protein­
truncating variants in TRIM28 are extremely rare in 
the general population, because the gene is highly 
intolerant to truncating variation, with a pLI score of 1·0 
(pLI >0·9 indicates extreme intolerance to protein­
truncating variants).12 We found no other cancers in 
individuals carrying TRIM28 mutations. We also did 
not find any TRIM28 protein­truncating variants in 
334 individuals with 27 other childhood cancers or in 
7632 individuals with adult cancers, suggesting that 
Figure 2: Schematic representations of TRIM28, FBXW7, NYNRIN, and KDM3B
Schematic representations of encoded proteins are shown, with functional domains in grey. The position of cancer-predisposing mutations is shown above the 
protein. Red symbols denote de novo mutations.
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Sex Mutations (protein change) Inheritance Tumour type, 
age at diagnosis 
(months)
Unilateral or 
bilateral
Histology Other Status, age 
(years)
TRIM28
ID_0477_01 F 929G→A (Gly310Asp) Maternal WT, 24 Unilateral Epithelial predominant ·· ··
ID_0477_02 M 929G→A (Gly310Asp) Maternal WT, 84 Unilateral Epithelial ·· ··
ID_0477_03 F 929G→A (Gly310Asp) Maternal WT, 93 Unilateral NA ·· ··
ID_0498_01 M 1746_1747delinsC Maternal WT, 8 Unilateral Epithelial ·· Alive, 30
ID_0498_02 F 1746_1747delinsC Maternal WT, 5 Unilateral Epithelial ·· Alive, 29
ID_0498_03 F 1746_1747delinsC NA WT, 6 Unilateral Epithelial ·· ··
ID_0487_01 M 429dupC Maternal WT, 15 Unilateral Epithelial predominant ·· Alive, 19
ID_0487_02 M 429dupC NA WT, 18 Unilateral NA ·· ··
ID_0506_01 M 525_526delGA Maternal WT, 39 Unilateral Epithelial ·· Alive, 23
ID_0506_02 F 525_526delGA Maternal WT, 8 Bilateral Epithelial ·· Alive, 20
ID_7487_01 F 239_245del7 Maternal WT, 118 Unilateral Epithelial predominant, 
diffuse anaplasia
·· Died, 12
ID_1982 M 1957delC De novo WT, 11 Bilateral Epithelial predominant ·· Alive, 15
ID_6530 M 209_210delAG De novo WT, 15 Unilateral Epithelial and blastemal Autism, speech delay Alive, 6
ID_1969 M 840–2A→G De novo WT, 118 Unilateral Epithelial and blastemal ·· Alive, 19
ID_7574 M 2508A→G (X836TrpextX?)* De novo WT, 13 Unilateral Epithelial predominant Autism, intellectual 
disability
··
ID_0902 F 1250C→A (Ser417X) Maternal WT, 12 Unilateral Epithelial predominant ·· ··
ID_0692 F 1459C→T (Arg487X) NA WT, 13 Bilateral NA ·· Alive, 36
ID_6671 F 688C→T (Arg230X) NA WT, 10 Bilateral Epithelial predominant Chronic kidney disease Alive, 6
ID_0796 F 1085T→A (Leu362X) NA WT, 61 Unilateral NA ·· Alive, 33
ID_0866 F 1300_1301dupAA NA WT, 90 Unilateral Epithelial predominant ·· Alive, 29
ID_0936 M 1150G→T (Glu384X) NA WT, 8 Unilateral NA ·· ··
FBXW7
ID_0811 M 710G→A (Trp237X) De novo WT, 76 Unilateral NA Osteosarcoma at 39 years Died, 39
ID_2084_01 M 1972C→T (Arg658X) NA WT, 42 Unilateral Focal anaplasia Relapse at 66 months ··
ID_0592 F 1017_1021del5 Paternal WT, 28 Unilateral NA hypotonia Alive, 18
ID_1227 F 670C→T (Arg224X) NA WT, 73 ·· NA ·· Died, 7
ID_7520 M 1753A→T (Ser585Cys) De novo Rhabdoid, 40 ·· Extra-renal rhabdoid 
with INI1 loss
Two febrile convulsions Alive, 5
NYNRIN
ID_0493_01 M 1955_1956delCA Paternal WT, 24 Unilateral Blastemal predominant Inguinal hernia ··
ID_0493_01 ·· 3761G→A (Trp1254X) Maternal ·· ·· ·· ·· ··
ID_0493_02 M 1955_1956delCA Paternal WT, 24 Unilateral Triphasic ·· ··
ID_0493_02 ·· 3761G→A (Trp1254X) Maternal ·· ·· ·· ·· ··
ID_6049 M 311G→A (Trp104X) Maternal WT, 34 Unilateral Triphasic Epilepsy, hypothyroidism, 
intellectual disability
Alive, 11
ID_6049 ·· 1295_1296del2ins31 Paternal ·· ·· ·· ·· ··
KDM3B
ID_7225 F 3422A→G (Asn1141Ser) De novo WT, 49 Bilateral NA Hyperpigmentation ··
ID_2086 M 916_917delAG De novo Hepatoblastoma, 
131
·· NA Autism, abnormal 
pigmentation, intellectual 
disability
··
CDC73
ID_6491_01 F 878dupA Paternal WT, 192 Unilateral Epithelial predominant Convergent strabismus Alive, 21
ID_6491_02 M 878dupA NA WT, 96 Unilateral NA ·· Alive, 48
Pedigrees and chromatograms are shown in the appendix. F=female. WT=Wilms tumour. M=male. NA=not available. *The stop codon (X) at position 836 is changed to Trp, extending the protein by an unknown 
number of amino acids (?). 
Table: Molecular and clinical features of individuals with mutations in TRIM28, FBXW7, NYNRIN, KDM3B, or CDC73
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TRIM28 pathogenic mutations primarily predispose to 
Wilms tumour. Of note, the TRIM28 mutations in two 
families in our study (ID_0498 and ID_0506) were 
independently, and coincidentally, reported while we 
were preparing this manuscript.18 We identified a de­
novo stop­loss mutation in another family (ID_7574), 
which we assumed to be pathogenic. Finally, in family 
ID_0477, which included six cases of Wilms tumour, we 
identified TRIM28 929G→A, leading to the protein 
change Gly310Asp (figure 2, table, appendix). We believe 
this mutation to be pathogenic because it is absent from 
public and in­house datasets, it segregates with Wilms 
tumour in the family, it is predicted to be deleterious by 
in silico tools, and it is at a crucial residue within the 
coiled­coil domain of TRIM28 that is reported to interact 
with AMER1, which is encoded by a gene somatically 
mutated in Wilms tumour.19
We established that ten of the TRIM28 mutations had 
been inherited, and that in all cases, the mutation had 
been transmitted from the mother, a significant association 
(p=0·00098). Pathology information was available for 
16 tumours, of which 14 were epithelial or epithelial­
predominant (table).
We identified truncating FBXW7 mutations in 
four individuals with Wilms tumour, of which one was 
de novo (in ID_0811), one had been inherited from an 
unaffected father (in ID_0592), and two were of 
unknown provenance (in ID_2084 and ID_1227; figure 2, 
table, appendix). FBXW7 is highly intolerant to protein­
truncating variants (pLI=1·00) and these data suggest 
that FBXW7 is a Wilms tumour predisposition gene. 
Two of the four individuals with truncating FBXW7 
mutations have died (table). Additionally, ID_2084 was 
treated for Wilms tumour at 3·5 years of age, but 
relapsed when he was 5·5 years old. We did not find 
truncating FBXW7 mutations in individuals with other 
childhood or adult cancers. However, we identified a de 
novo non­synonymous mutation, 1753A→T (protein 
change Ser585Cys), in a child with an extra­renal 
rhabdoid tumour (ID_7520), which we assumed to be 
pathogenic.
We identified biallelic truncating mutations in 
NYNRIN in three children from two families (ID_0493 
and ID_6049; figure 2, table, appendix). Each parent was 
heterozygous for one of the mutations. These mutations 
were absent from ExAC and the ICR1000 series. We 
found no individuals with two NYNRIN truncating 
mutations in the ICR1000 series and no homozygous 
protein­truncating variants in ExAC (individual­level data 
is not available for ExAC, therefore it is not possible to 
know if anyone had two different protein­truncating 
variants). Additionally, the probability of finding two 
different families with the same phenotype and two 
truncating NYNRIN mutations by chance is 4·0 × 10–⁹. 
One of the affected children had an inguinal hernia and 
another had epilepsy, hypothyroidism, and intellectual 
disability (table). It is unclear whether any of these 
additional clinical features are related to the biallelic 
NYNRIN mutations. We did not identify biallelic 
NYNRIN protein­truncating variants in individuals with 
other childhood or adult cancers.
In addition to the agnostic protein­truncating variant 
prioritisation analyses, we reviewed the exome data in 
genes proposed as possible childhood cancer pre dis­
position genes, identified through a systematic review of 
19 171 genes for links to Mendelian disease. This review 
led us to the identification of two de­novo KDM3B 
mutations, a non­synonymous mutation in a child with 
Wilms tumour and a hyperpigmented lesion on her 
buttock (ID_7225) and a truncating mutation in a child 
with hepatoblastoma, hyperpigmentation and hypo­
pigmentation, autism, and intellectual disability (ID_2086; 
figure 2, table, appendix). In 2018, Diets and colleagues20 
reported a KDM3B truncating mutation in a girl with 
acute myeloid leukaemia, mild intellectual disability, and 
hip dysplasia and a de novo non­synonymous KDM3B 
mutation in a boy with Hodgkins lymphoma and 
moderate intellectual disability. KDM3B is highly 
intolerant to both protein­truncating variants (pLI=1·00) 
and non­synonymous variation (Z=4·99; the Z score is the 
deviation of observation from expectation for non­syn­
onymous variants). Taken together, these data provide 
strong evidence that KDM3B is a childhood cancer pre­
disposition gene.
These new discoveries bring the number of con­
stitutionally mutated genes confirmed as Wilms tumour 
predisposition genes to 21. We estimate that, together, 
these constitutional events contribute to about 10% of 
unselected Wilms tumour (figure 3). Four contributors—
WT1, TRIM28, REST, and 11p15 epimutations and 
uniparental disomy that result in biallelic IGF2 
expression—each account for about 2%.2,4,5 The remain­
ing 17 are very rare and, together, probably account for 
no more than 2% of unselected Wilms tumours.2–4,6–11 
Functional enrichment analysis highlighted nucleic acid 
metabolism, chromosome organisation, chromatin or 
histone modification, and negative regulation of cellular 
processes as important pathways underlying Wilms 
tumour predisposition (appendix).
We have investigated 65 families with two or more cases 
of Wilms tumour over the last 20 years, including the 49 
familial Wilms tumour pedigrees in this study (appendix). 
In two families, we found a constitutional predisposing 
mutation in one individual with Wilms tumour, but not 
their affected relative. We have identified causative 
constitutional mutations in 22 (35%) of the remaining 
63 families (figure 3). The most common of which were 
mutations in REST (five [8%] of 63), TRIM28 (five [8%] of 
63), and WT1 (four [6%] of 63). CTR9 mutations were 
present in three families and H19 hypermethylation was 
found in two families. Biallelic BRCA2 mutations, biallelic 
NYNRIN mutations, and a CDC73 mutation were found 
in one family each. We identified the CDC73 mutation 
through this present study (table, appendix). CDC73 is an 
For the overview of the 
19 171 genes and their 
association with Mendelian 
disease see https://osf.io/s4pva/
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established Wilms tumour predisposition gene but, to our 
knowledge, has not previously been associated with 
familial Wilms tumour. We did not find any cause in two 
thirds of the families (41 [65%] of 63). 
Finally, we assessed the overlap between the 21 Wilms 
tumour predisposition genes and 20 somatically mutated 
Wilms tumour driver genes (figure 4). Only four genes—
WT1, IGF2, TP53, and DICER1—promoted Wilms 
tumour oncogenesis in both contexts, and all four were 
also somatically altered in other cancers. A further five 
constitutionally mutated genes—PIK3CA, FBXW7, 
ASXL1, BRCA2, and CDC73—were somatically mutated 
in other cancer types but have not been proven to be 
somatic drivers in Wilms tumour. The remaining 
12 Wilms tumour predispos ition genes are not known to 
be somatically mutated cancer drivers.
Discussion
To our knowledge, this is the largest exome sequencing 
study of individuals with Wilms tumour to date, 
including 890 affected individuals. Our analyses found 
three autosomal dominant Wilms tumour predisposition 
genes—TRIM28, FBXW7, and KDM3B—and one auto­
somal recessive Wilms tumour predisposition gene, 
NYNRIN. Constitutional TRIM28 mutations join 
constitutional WT1 and REST mutations as a relatively 
common contributor to Wilms tumour predisposition, 
accounting for about 8% of familial Wilms tumour and 
about 2% of unselected Wilms tumour.2,4 We found a 
strong association between TRIM28 mutations and 
epithelial Wilms tumour, with most individuals with a 
TRIM28 mutation having Wilms tumour of pre­
dominantly epithelial histology. This suggests that 
TRIM28 mutations make a sizeable contribution to 
epithelial Wilms tumour, and we recommend that all 
children with this rare favourable subtype of Wilms 
tumour should be offered TRIM28 gene testing.
Familial Wilms tumour pedigrees due to TRIM28 
mutations showed incomplete penetrance and a strong 
parent­of­origin effect, because all inherited mutations 
Figure 3: Contribution of constitutional mutations to unselected and familial Wilms tumour
(A) About 10% of unselected Wilms tumours are due to constitutional mutations in one of 21 genes (pink). (B) A third of familial Wilms tumours are explicable by 
known Wilms tumour predisposition factors (pink) and two thirds are of unknown cause (blue). 
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were maternally transmitted. TRIM28 is not imprinted, 
but it is located close to PEG3, which is imprinted and 
paternally expressed.21 At the organism level, PEG3 
promotes growth but at the cellular level, it is a putative 
tumour suppressor.21 A possible explanation for the 
maternal bias of TRIM28 mutations is that somatic 
inactivation of the paternal wild­type TRIM28 allele, 
through mitotic recombination, also leads to loss of the 
paternally expressed PEG3, thus promoting tumouri­
genesis. There is precedence for this model in cancer 
predisposition: SDHD mutations predispose to phaeo­
chromocytoma almost exclusively when inherited 
paternally.22 The combination of somatic loss of the 
maternal wild­type SDHD allele and maternally expressed 
growth inhibitory genes at the IGF1–H19 imprinting 
region has been proposed as the explanation for this 
pattern.22 However, a factor against this model for TRIM28 
is that the loss of heterozygosity in the tumour from 
ID_506_01 did not appear to include PEG3.18 Given the 
prevalence of TRIM28 mutations in Wilms tumour, 
confirmation of the parent­of­origin bias we observed 
should be possible in the near future. If this parent­of­
origin effect is supported, DNA methylation analyses at 
the PEG3 imprinting control region and loss of 
heterozygosity and PEG3 expression analyses in tumours 
from individuals with TRIM28 mutations might help 
to provide a mechanistic explanation. From a clinical 
perspective, establishing if the penetrance of TRIM28 
mutations is influenced by the parent­of­origin of the 
mutation is important, because this would have consider­
able impact on cancer risks and genetic counselling.
We provided evidence that constitutional FBXW7 
mutations predisposed to Wilms tumour and to other 
malignancies. Two of the five individuals carrying FBXW7 
mutations had a malignancy other than Wilms tumour. 
ID_0811 developed osteosarcoma as an adult, after having 
Wilms tumour. ID_7520 had a rhabdoid tumour and did 
not have Wilms tumour. The assessment of additional 
individuals with rhabdoid tumour and de­novo FBXW7 
mutations would be useful to further support the role of 
FBXW7 in rhabdoid tumour predisposition. Furthermore, 
a woman with Hodgkin lymphoma, adult Wilms tumour, 
early­onset breast cancer, and a constitutional FBXW7 
deletion was reported in 2015,23 and a man with renal cell 
cancer and a constitutional t(3;4)(q21;q31) translocation 
dis rupting FBXW7 was reported in 2009.24 These data 
suggest that individuals with FBXW7 mutations might be 
at risk of multiple childhood and adult cancers and will 
require ongoing close monitoring. Notably, we believe that 
the in­frame FBXW7 variant reported25 in an individual 
with Wilms tumour is not pathogenic because it is not 
rare and the child also had a pathogenic WT1 mutation.
KDM3B also appears to be a pleiotropic cancer 
predisposition gene. The four KDM3B pathogenic 
mutations reported to date have been associated with 
four different cancers: Wilms tumour and hepato­
blastoma in our study, and acute myeloid leukaemia and 
Hodgkin lymphoma in the study by Diets and 
colleagues.20 Large­scale, broad mutation testing of 
FBXW7 and KDM3B in individuals with cancer will 
probably be required to establish the full spectrum of 
associated cancers, because of the rarity of truncating 
variants and the challenges in interpreting non­
synonymous variation in these genes. There are 
indications that KDM3B and NYNRIN mutations might 
cause non­malignant pheno types, particularly intellectual 
disability. More data on the contribution of these genes to 
non­malignant conditions will probably become available 
over the next decade through extensive exome and 
genome sequencing being done in children with develop­
mental disorders.
The four genes we reported here have different 
functions, and it is unclear why or how they predispose to 
Wilms tumour. TRIM28 encodes a multidomain protein 
involved in the regulation of many cellular processes, 
including transcriptional repression, p53 degradation, 
pluripotency maintenance, autophagosome formation, 
epithelial­mesenchyme transition, and the DNA damage 
response.26 TRIM28 is highly expressed in many cancers, 
and its inactivation has not been previously associated 
with oncogenesis. This might explain why inactivating 
TRIM28 mutations seem to predispose to Wilms tumour 
alone. The mechanisms underlying this Wilms tumour 
pre dis position are not known, but it is notable that 
TRIM28 is a major binding partner of AMER1, which is 
encoded by a gene that is frequently somatically mutated 
in Wilms tumour.19
FBXW7 encodes the substrate recognition component of 
the E3­ubiquitin ligase SCF complex, which is responsible 
for recognising and binding phosphorylated substrates 
and regulating their turnover through proteosome 
degradation.27 FBXW7 is an established tumour suppressor 
gene and frequently mutated in many cancers, particularly 
endometrial and gastro intestinal cancers.27 FBXW7 is not a 
confirmed somatic driver in Wilms tumour because only 
one confirmed somatic FBXW7 point mutation has thus 
far been reported.25 This situation is similar to that of 
PIK3CA. Constitutional mosaic PIK3CA mutations pre­
dispose to Wilms tumour, whereas somatic mutations at 
the same residue are common in many cancers but have 
not been reported in Wilms tumour.9
KDM3B encodes a histone H3 demethylase that 
specifically catalyses the demethylation of H3K9Me1 and 
H3K9Me2 residues, and is required for normal somatic 
growth in mice.28 Tumour­suppressive and tumour­
promoting KDM3B activities have been proposed in 
leukaemia, although somatic driver KDM3B mutations 
have not been reported. Finally, there is very little known 
about the functions of NYNRIN, though NYN domains are 
thought to be involved in RNA processing and NYNRIN 
has been implicated in microRNA–mRNA regulation.29
The diverse functions of these four new Wilms tumour 
predisposition genes mirror the broad range of biological 
processes in which known Wilms tumour predisposition 
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genes operate, as shown by our functional enrichment 
analysis (appendix). Functional exploration of these 
genes was beyond the scope of our study, but we hope 
our results might encourage such assessments, which 
will probably provide novel insights into oncogenesis 
and kidney development.
Our analyses were designed to identify tumour 
suppressor genes in which constitutional truncating 
mutations predisposed to cancer, but were not designed 
to identify other mechanisms of cancer predisposition. 
For example, it is very possible that non­truncating 
coding variation might be contributing to familial and 
non­familial Wilms tumour, and future analyses to 
investigate this would be worthwhile. Non­coding, 
epigenetic, and mosaic abnormalities are all known to 
be relevant to Wilms tumour predisposition but were 
not investigated in our study. Notably, none of the 
known Wilms tumour predisposition genes are within 
the regions on chromosomes 2p24, 11q14, 5q14, 22q12, 
and Xp22 identified in a genome­wide association 
study30 of Wilms tumour, and the causal mechanisms 
underlying the associations in that study are unknown. 
Additionally, the mutations at 17q21 responsible for 
FWT1­linked families have not yet been discovered.2
Genetic predisposition to Wilms tumour exhibits 
remarkable heterogeneity, and this is particularly 
noteworthy because childhood cancers are generally 
assumed to be aetiologically simpler than adult cancers. 
Furthermore, our study provides strong evidence that 
further genetic, genomic, or epigenetic Wilms tumour 
predisposition factors exist, because only a third of the 
familial Wilms tumour pedigrees we investigated have 
been explained. Any further familial Wilms tumour 
genes discovered will be highly likely to contribute also to 
non­familial Wilms tumour.
Our study reveals new insights into the complexity, 
mechanisms, and clinical implications of Wilms tumour 
predisposition. Although our understanding of the 
genetic landscape of Wilms tumour predisposition is still 
far from complete, the available knowledge has 
considerable scientific and clinical use. Given the 
extensive heterogeneity and the absence of family history 
or additional clinical features in many individuals with a 
mutation, we believe routine genetic testing in all 
individuals with Wilms tumour would be scientifically 
and clinically valuable.
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